HER2+ Metastatic Breast Cancer Treatment Landscape – Current Choices, Future Possibilities

White Paper: HER2+ Metastatic Breast Cancer Treatment Landscape – Current Choices, Future Possibilities

Therapeutic Landscape for Treatment of HER2+ mBC Continues to Evolve

Given the complexity of treatment choices in HER2+ mBC, Premier and Genentech partnered to understand treatment decision-making factors in this setting and to facilitate a user experience forum to explore community-based oncologists’ perceptions of the HER2+ mBC treatment landscape and decision-making approaches.

Premier conducted the web-based forum/panel discussion with six community-based oncologists (“Advisors”) with expertise in breast, head and neck cancers, as well as hematology.

Download the white paper to learn more about this discussion and treatments.

CONTACT INFORMATION

Premier is committed to protecting the privacy and security of any personal information you provide to us. By clicking here, you understand and acknowledge that the personal information that you are submitting on this form is subject to Premier's privacy policy.